

**WOMBLE
CARLYLE
SANDRIDGE
& RICE**

A PROFESSIONAL LIMITED
LIABILITY COMPANY

**RECEIVED
CENTRAL FAX CENTER
OCT 20 2006**

ATLANTA
CHARLOTTE
RALEIGH
RESEARCH TRIANGLE PARK
WASHINGTON, D.C.
WINSTON-SALEM

FACSIMILE

From: Mengmeng Fahrni
Direct Dial: (404) 879-2470
Direct Fax: (404) 888-7490
E-Mail: mfahrni@wcsr.com

TO:	Commissioner for Patents	COMPANY:	USPTO
FAX:	571-273-8300	PAGES:	(including cover) 166
PHONE:		DATE:	October 20, 2006
RE:	Information Disclosure Statement	ATTORNEY DOCKET/REF. NO.	C261-1030.1
		ACCOUNTING NO.	51081 0003.8

☐ Urgent ☐ For Review ☐ Please Comment ☐ Please Reply ☐ Please Recycle

CONFIDENTIAL AND PRIVILEGED: The information contained in this facsimile is privileged and confidential information intended for the sole use of the addressee. If the reader of this facsimile is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this FAX in error, please immediately notify the person listed above, and return the original message by mail to the sender at the address listed above.

Please call the following number if the message you receive is incomplete or not legible: 404-879-2470 Diana Ogles

In Re application of Ghost, et al.

Serial No. 10/698,863

Filed: November 3, 2003

For: Method of Treating and/or Preventing Asthma Using Natural Compound Luteolin

Attached for filing in the above-referenced matter are the following documents:

1. Information Disclosure Statement
2. PTO Form SB08A
3. References A - I

10/23/2006 TL0111 00000054 090528 10698863
01 FC:1806 180.00 DA

1201 West Peachtree Street, Suite 3500

Atlanta, GA 30309-3574

Telephone (404) 872-7000

Fax: (404) 888-7490

WCSR 3460725v1

RECEIVED
CENTRAL FAX CENTER
OCT 20 2006

002/173

be applied as references, and/or to prove that some of the cited information may not be prior art, and/or to prove that some of the cited information may not be enabling for the teachings they purport to offer.


This statement further should not be construed as a representation that an exhaustive search has been made, or that the information cited herewith is material, or that there does not exist information more material to the examination of the present Application. The Examiner is specifically requested not to rely solely on the information submitted herein. On the contrary, the Examiner is requested to conduct a thorough review of the information, and to form independent opinions as to its significance.

In accordance with 37 CFR 1.97(c) and 1.17(p), Applicant authorizes the commissioner to charge \$180.00 to our Deposit Account No. 09-0528 representing the filing fee for filing this Information Disclosure Statement.

It is respectfully requested that the Examiner initial and return copies of the enclosed form(s) PTO/SB/08 and indicate in the official file wrapper of the above-identified patent application that each item of the cited information has been considered.

The Commissioner is hereby authorized to charge any additional fees that may be required, or credit any overpayment to account no. 09-0528.

Respectfully submitted,



Mengmeng Anne Fahrni, PhD, Patent Agent
Reg# 57,717
For David S. Bradin
Attorney for Applicant
Registration No. 37,783

Date: Oct. 20, 2006

Womble Carlyle Sandridge & Rice, PLLC
P.O. Box 7037
Atlanta, GA 30357-0037
(404) 872-7000 (Telephone)
(404) 888-7490 (Facsimile)
Docket No.: C261 1030.1

OCT 20 2006

PTO/SB/08A (07-05)

Approved for use through 07/31/2005. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/698,863		
		Filing Date	November 3, 2003		
		First Named Inventor	Ghost		
		Art Unit	1654		
		Examiner Name	Michele C. Flood		
Sheet	1	of	1	Attorney Docket Number	C261 1030.1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
	A	GUPTA, et al.; "Corticosteroids: The Mainstay in Asthma Therapy;" <u>Bioorganic & Medicinal Chemistry</u> ; 12/24/2003; pp. 6331 - 6342; Vol. 12; Elsevier, Ltd.
	B	JONES, et al.; "Quercetin, Flavonoids, and the Life-Span of Mice;" <u>Experimental Gerontology</u> ; 09/15/1981; pp. 213 - 217; Vol. 17; Pergamon Press, Ltd.
	C	GALATI, et al.; "Potential Toxicity of Flavonoids and Other Dietary Phenolics: Significance for Their Chemopreventative and AntiCancer Properties," <u>Free Radical Biology & Medicine</u> ; 12/11/2003; pp. 287 - 303; Vol. 37; Elsevier, Inc.
	D	BARNES, et al.; "Inflammatory Mediators of Asthma: An Update," <u>Pharmacological Reviews</u> ; 1998; pp. 515 - 595; Vol. 50, No. 4; The American Society for Pharmacology and Experimental Therapeutics
	E	KIM, et al.; "Anti-inflammatory Plant Flavonoids and Cellular Action Mechanisms," <u>Journal of Pharmacological Sciences</u> ; 2004; pp. 229 - 245; Vol. 96; Japanese Pharmacological Society
	F	SIMON, et al.; "Adverse Reaction to Aspirin and Nonsteroidal Antiinflammatory Drugs (NSAIDs)," <u>Allergy & Immunology</u> ; 2003; pp. 239 - 251; Vol. 24, No. 3; Humana Press
	G	NAMAZY, et al.; "Sensitivity to Nonsteroidal Anti-inflammatory Drugs;" <u>Annals of Allergy, Asthma, & Immunology</u> ; 04/08/2002; pp. 542 - 550; Vol. 89; Allergy, Asthma, and Immunology, Scripps Clinic
	H	LUNNI, et al.; "Inhibition of Neutrophil Phospholipase A ₂ by p-Bromophenylacetyl Bromide, Nordihydroguaiaretic Acid, 5, 8, 11, 14 - Eicosatetraenoic Acid and Quercetin;" <u>Int. Archs Allergy Appl. Immun.</u> ; 1985; pp. 214 - 217; Vol. 76; Krager, AG
	I	LEE, et al.; "Effects of Quercetin on Human Polymorphonuclear Leukocyte Lysosomal Enzyme Release and Phospholipid Metabolism;" <u>Life Sciences</u> ; 1982; pp. 2765 - 2774; Vol. 31; Pergamon Press, Ltd.
EXAMINER'S SIGNATURE:		DATE CONSIDERED: